US Channels $4.5B in Global Health Aid Through New APS
By @sharedot · · 7 pages
- Health
- Global Health
- Foreign Aid
A new State Department competitive mechanism could direct up to $4.5 billion to MOU countries and five health areas, reshaping post-USAID aid.
What Happened: A New Funding Engine for America First Aid
The State Department has quietly built a new vehicle to move money under its America First Global Health Strategy: the Advancing Global Health Annual Program Statement (AGH/APS), an open-ended competitive funding mechanism announced in March 2026.
According to a KFF policy brief published November 13, the department anticipates using the AGH/APS to provide up to $4.5 billion across four funding windows from March 2026 through February 2027, with individual awards ranging from $500,000 to $250 million over five years.
The mechanism supplements the bilateral memoranda of understanding the US has signed directly with partner countries — 36 agreements totaling $26.7 billion so far, with the US committing $15.9 billion and partners co-investing $10.3 billion, per KFF.
Eligible applicants range from governments and universities to NGOs, faith-based organizations, and private companies.
Why It Is Surprising: Aid Isn't Dead, It's Changing
Many Americans assumed the US was out of the global health business after the first-day withdrawal from the World Health Organization, the aid pause, and the dissolution of USAID, which brought documented shortages of tuberculosis, malaria, and HIV drugs and widespread clinic closures.
Yet as The New York Times reports, American global health aid isn't dead — it's changing.
Congress still wanted its roughly $10 billion in main global health funding spent, and the September 2025 strategy endorsed goals experts have long backed, like shifting program responsibility to recipient countries.
The Times also notes the unusual strings attached: countries were invited to negotiate agreements that, in Secretary of State Marco Rubio's words, 'promote our national interests while saving millions of lives.'
The Evidence: 12 Addenda, $1.43 Billion, 122 Awards
KFF's analysis counts 12 addenda released across three funding rounds as of November 2026, totaling up to $1.43 billion and representing up to 122 possible awards — nearly a third of the anticipated $4.5 billion.
Seven addenda target specific MOU countries: Cameroon, Cote d'Ivoire, Malawi, Mozambique, Nigeria, the Philippines, and Uganda, accounting for 54% of possible awards and up to $730 million, roughly 10% of the $7.3 billion in US funding expected under those countries' MOUs.
Five addenda focus on health areas outside the MOU envelopes — child development, care, and protection; neglected tropical diseases; nutrition; population-based surveys and surveillance; and rapid outbreak response — with outbreak response drawing the largest area funding at up to $290 million, per KFF.
The Stakes: Sovereignty Friction in Africa
The bilateral deals at the heart of this strategy are meeting real resistance.
World Politics Review reports that Zambia signed a $2.49 billion health financing agreement on October 8 after months of negotiations, a Kenyan appellate court cleared a similar framework deal to proceed pending further appeals, and Ghana reopened talks after its Cabinet had rejected a proposed deal.
With Zambia's signature, 25 African countries have signed bilateral deals under the strategy, out of 36 globally — but WPR stresses the signatories are not a straightforward win for Washington, since African leaders pushed back on US demands and won important concessions, asserting sovereignty in the negotiations.
What Comes Next: Awards Still Unannounced
The AGH/APS process remains underway. A fourth funding window is expected to run from November 15, 2026 through January 29, 2027, and additional addenda are anticipated as part of the last round, according to KFF.
At this time no awards have been publicly announced, and it is not known what will actually be funded.
KFF notes that how the mechanism and specific awards operate to support or supplement the MOUs — whose own implementation plans are still to come, with government-to-government funding agreements described as nascent and expected to take time to develop — will be important to monitor.
Objectives across the addenda already range from strengthening disease surveillance and supply chains to building government capacity for financing and data systems, signaling where the money may land.